Logo.png
Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021
December 01, 2021 16:05 ET | Cocrystal Pharma, Inc.
Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) --...
Rubius_Logo.jpg
Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
October 01, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 07:30 ET | Wave Life Sciences USA, Inc.
Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clinical trials in...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
June 02, 2021 16:52 ET | Wave Life Sciences USA, Inc.
First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating...
Rubius_Logo.jpg
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
May 12, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
logo.gif
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
April 13, 2021 07:45 ET | Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
Pandion-Logo-RGB-large.png
Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
February 22, 2021 08:30 ET | Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
January 11, 2021 08:00 ET | Wave Life Sciences USA, Inc.
Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease...
TBIO.jpg
Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies
October 15, 2020 08:00 ET | Translate Bio, Inc.
-- mRNA-based vaccine candidate MRT5500 induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies -- -- Two doses of MRT5500 induced neutralizing antibody levels significantly...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
September 15, 2020 07:30 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...